60.50
1.92%
+1.14
Handel nachbörslich:
60.50
Überblick
Nachrichten
Preisverlauf
Optionskette
Financials
Warum fällt CYTK?
Forum
Prognose
Aktiensplit
Cytokinetics Inc Aktie (CYTK) Neueste Nachrichten
Cytokinetics Announces Five Presentations Related to Aficamten at the European Society of Cardiology Congress 2024
GlobeNewswire Inc.
Cytokinetics Announces Primary Results From SEQUOIA-HCM Presented in Late Breaking Clinical Trial Session at the European Society of Cardiology Heart Failure 2024 Congress and Published in the New England Journal of Medicine
GlobeNewswire Inc.
Cytokinetics (CYTK) Reports Q1 Loss, Lags Revenue Estimates
Zacks Investment Research
Cytokinetics Reports First Quarter 2024 Financial Results
GlobeNewswire Inc.
Cytokinetics Announces Start of CEDAR-HCM, a Clinical Trial of Aficamten in a Pediatric Population With Symptomatic Obstructive Hypertrophic Cardiomyopathy
GlobeNewswire Inc.
Cytokinetics to Hold Annual Meeting of Stockholders
GlobeNewswire Inc.
Omega Therapeutics, Inc. (OMGA) Reports Q1 Loss, Tops Revenue Estimates
Zacks Investment Research
Cytokinetics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
GlobeNewswire Inc.
Geron (GERN) Reports Q1 Loss, Tops Revenue Estimates
Zacks Investment Research
Should Vanguard S&P Small-Cap 600 ETF (VIOO) Be on Your Investing Radar?
Zacks Investment Research
Cytokinetics (CYTK) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release
Zacks Investment Research
Cytokinetics to Host Investor Event and Conference Call to Discuss the Primary Results From SEQUOIA-HCM at the European Society of Cardiology Heart Failure 2024 Congress
GlobeNewswire Inc.
Cytokinetics to Announce First Quarter Results on May 8, 2024
GlobeNewswire Inc.
Cytokinetics Announces Three Late Breaking Clinical Trial Presentations Relating to SEQUOIA-HCM at the European Society of Cardiology Heart Failure 2024 Congress
GlobeNewswire Inc.
Cytokinetics Presents Additional 48-Week Data From FOREST-HCM, the Open Label Extension Clinical Study of Aficamten, at The American College of Cardiology 73ʳᵈ Annual Scientific Session
GlobeNewswire Inc.
Cytokinetics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
GlobeNewswire Inc.
Cytokinetics to Participate in the 23rd Annual Needham Virtual Healthcare Conference
GlobeNewswire Inc.
Cytokinetics Announces Four Upcoming Presentations at the American College of Cardiology 73rd Annual Scientific Session
GlobeNewswire Inc.
2 Incredible Growth Stocks to Buy Right Now
The Motley Fool
Cytokinetics to Participate in March Investor Conferences
GlobeNewswire Inc.
Cytokinetics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
GlobeNewswire Inc.
This biotech ETF sees ‘breakout’ while U.S. small-cap technology stocks lag
MarketWatch
Cytokinetics Joins Global Initiative to Recognize International Rare Disease Day
GlobeNewswire Inc.
Cytokinetics (CYTK) Reports Q4 Loss, Misses Revenue Estimates
Zacks Investment Research
Cytokinetics Reports Fourth Quarter 2023 Financial Results
GlobeNewswire Inc.
Cytokinetics to Announce Fourth Quarter Results on February 27, 2024
GlobeNewswire Inc.
Cytokinetics to Participate in the Oppenheimer 34th Annual Healthcare Life Sciences Conference
GlobeNewswire Inc.
Banco Santander, Lloyds Banking And Other Big Stocks Moving Lower In Monday's Pre-Market Session
Benzinga
Tarsus Pharmaceuticals, Inc. (TARS) Moves 8.5% Higher: Will This Strength Last?
Zacks Investment Research
Cytokinetics Announces Recipients of Its Sixth Annual Communications Grant Program
GlobeNewswire Inc.
Cytokinetics Presents New Data at CMR 2024 From FOREST-HCM, the Open Label Extension Clinical Trial of Aficamten
GlobeNewswire Inc.
Cytokinetics Announces New Data From FOREST-HCM to be Presented at CMR 2024
GlobeNewswire Inc.
Novartis' (NVS) Strong Portfolio, Pipeline to Fuel Growth in 2024
Zacks Investment Research
Cytokinetics (CYTK) Down on Report of Novartis Not Interested
Zacks Investment Research
Cytokinetics' Heart Drug Is A Multi-Billion Dollar Opportunity By 2032 Despite Novartis Setback: Analyst
Benzinga
Wall Street Breakfast Podcast: EV Names Fall As Hertz Hits The Gas Pedal
Seeking Alpha
Aspen Aerogels Issues Business Update, Joins Plug Power, SunPower And Other Big Stocks Moving Lower On Thursday
Benzinga
Cytokinetics (CYTK) Rises on Reports of Buyout by Novartis
Zacks Investment Research
GSK to buy asthma drug developer for up to $1.4 billion in pipeline push
MarketWatch
CACI International To Rally Around 21%? Here Are 10 Top Analyst Forecasts For Friday
Benzinga
Cytokinetics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
GlobeNewswire Inc.
2 Biotechs That Could Get Bought Out in 2024
The Motley Fool
Cytokinetics to Present at the 42nd Annual J.P. Morgan Healthcare Conference
GlobeNewswire Inc.
Cytokinetics' Drug Potential: Analyst Suggests Key Role Of Established Pharma For Potential Launch
Benzinga
Cytokinetics (CYTK) Up 83% as Cardiomyopathy Drug Meets Goals
Zacks Investment Research
Biotech Stock Roundup: BMY's KRTX and RYZB Acquisition, CYTK Surges on Study Data
Zacks Investment Research
Microsoft To Rally Over 20%? Here Are 10 Top Analyst Forecasts For Thursday
Benzinga
Company News for Dec 28, 2023
Zacks Investment Research
Dow Jones posts record close as stocks end mostly higher
MarketWatch
Crude Oil Falls Over 1%; First Wave BioPharma Shares Spike Higher
Benzinga
Kapitalisierung:
|
Volumen (24h):